^
Association details:
| Biomarker: | TET1 mutation |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Published date:
04/08/2022
Excerpt:
The overall survival of patients with TET1 mutations in the ICI-treated cohort was significantly longer than those without (p = 0.0059). Additionally, the patients with TET1 mutations were found to be more sensitive to lapatinib and 5-fluorouracil. These findings suggest that TET1 mutations may serve as a potential biomarker for the response to ICIs in COAD patients.
Secondary therapy:
5-fluorouracil
DOI:
https://doi.org/10.1186/s12957-022-02581-7
